Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
01 February 2024Website:
http://www.fibrobiologics.comNext earnings report:
30 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 19:55:01 GMTDividend
Analysts recommendations
Institutional Ownership
FBLG Latest News
HOUSTON, June 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the development of a novel artificial thymus organoid that can restore immune function in a severe combined immunodeficiency (SCID) mouse model.
HOUSTON, June 13, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today it is set to join the Russell 2000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24.
HOUSTON, June 06, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that Chief Scientific Officer, Hamid Khoja, Ph.D., will present on FibroBiologics' wound care and psoriasis programs at the Extracellular Matrix (ECM) Pharmacology Congress in Copenhagen, Denmark, from June 17-19, 2024. The ECM Pharmacology Congress is a forum to bring leading experts across borders and generations together to discuss how to modulate the ECM in different disease areas.
HOUSTON , March 13, 2024 /PRNewswire/ -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it will present an oral and poster presentation at the Advanced Wound Care Summit USA in Boston, Massachusetts, from April 16-17, 2024. The Advanced Wound Care Summit USA is a forum where industry leaders share the latest innovations and advancements in Wound Care and tackle pressing challenges in areas such as regulation, clinical trials, reimbursement, and investment.
HOUSTON , Feb. 20, 2024 /PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics") is a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. FibroBiologics will present in vitro and in vivo preclinical data using allogeneic human dermal fibroblasts (HDFs) and HDF spheroids as well as primary safety phase 0/1 clinical trial data for the single-dose infusion of HDFs during the poster sessions at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 on Thursday, February 29, at the Palm Beach County Convention Center and the Hilton West Palm Beach in West Palm Beach, Florida.
What type of business is FibroBiologics Common Stock?
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
What sector is FibroBiologics Common Stock in?
FibroBiologics Common Stock is in the Healthcare sector
What industry is FibroBiologics Common Stock in?
FibroBiologics Common Stock is in the Biotechnology industry
What country is FibroBiologics Common Stock from?
FibroBiologics Common Stock is headquartered in United States
When did FibroBiologics Common Stock go public?
FibroBiologics Common Stock initial public offering (IPO) was on 01 February 2024
What is FibroBiologics Common Stock website?
https://www.fibrobiologics.com
Is FibroBiologics Common Stock in the S&P 500?
No, FibroBiologics Common Stock is not included in the S&P 500 index
Is FibroBiologics Common Stock in the NASDAQ 100?
No, FibroBiologics Common Stock is not included in the NASDAQ 100 index
Is FibroBiologics Common Stock in the Dow Jones?
No, FibroBiologics Common Stock is not included in the Dow Jones index
When does FibroBiologics Common Stock report earnings?
The next expected earnings date for FibroBiologics Common Stock is 30 August 2024